Discussion
NKX019, Nkarta‘s experimental cell therapy, showed encouraging early safety results, with no reported cases of certain serious immune-related complications among 40 people with autoimmune diseases, including ANCA-associated vasculitis (AAV). The findings come from two ongoing Phase 1/2 clinical trials, dubbed Ntrust-1 (NCT06557265) and Ntrust-2 (NCT06733935), the…